All AbMole products are for research use only, cannot be used for human consumption.
Perifosine is a novel p.o. bioavailable alkylphospholipid. Perifosine has displayed significant antiproliferative activity in vitro and in vivo in several human tumor model systems and has recently entered phase I clinical trials. Perifosine causes dose-dependent inhibition of protein kinase B/Akt phosphorylation and thus activation at concentrations causing growth inhibition of PC-3 prostate carcinoma cells. Only the myristoylated form of Akt (MYR-Akt), which bypasses the requirement for pleckstrin homology (PH) domain-mediated membrane recruitment, abrogated perifosine-mediated decrease of Akt phosphorylation and cell growth inhibition by perifosine. Perifosine decreases the plasma membrane localization of Akt, and this is substantially relieved by MYR-Akt along with relief of downstream compound effect on induction of p21(WAF1/CIP1). Perifosine does not directly affect phosphoinositide 3-kinase (PI3K), phosphoinositide-dependent kinase 1, or Akt activity at concentrations inhibiting Akt phosphorylation and membrane localization.
Dev Comp Immunol. 2023 Aug 6;148:104905.
IRF9 inhibits CyHV-3 replication by regulating the PI3K-AKT signalling pathway in common carp (Cyprinus carpio) epithelial cells
Perifosine purchased from AbMole
J Hepatol. 2022 Nov 9;S0168-8278(22)03285-8.
Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice
Perifosine purchased from AbMole
Front Oncol. 2021 Apr 1;11:649176.
Akt Inhibition Enhanced the Growth Inhibition Effects of Low-Dose Heavy-Ion Radiation via the PI3K/Akt/p53 Signaling Pathway in C6 Glioblastoma Cells
Perifosine purchased from AbMole
Drυg Discοv Ther. 2020 Sep 8;14(4):197-203.
MicroRNA analysis of NCI-60 human cancer cells indicates that miR-720 and miR-887 are potential therapeutic biomarkers for breast cancer
Perifosine purchased from AbMole
 |
Source | Drug Discoveries & Therapeutics 2020. Figure 4. perifosine (Abmole Bioscience Inc, Houston, TX, USA) |
| Method | MTT assay | |
| Cell Lines | A549, H460, H322M, MCF-7, T47-D and MDA-MB-231 cells | |
| Concentrations | - | |
| Incubation Time | 72 h | |
| Results | The current study verified that the anti-cancer effect of perifosine was significantly enhanced by inhibiting miR-720 and that the anti-cancer effect of 5-Fu was significantly enhanced by inhibiting miR-887 in breast cancer cells |
| Cell Experiment | |
|---|---|
| Cell lines | MM cells |
| Preparation method | Growth inhibition assay. The inhibitory effect of perifosine, alone or combined with other agents, on MM cell growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International, Temecula, CA) dye absorbance. Cells were pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hours of 24-hour and/or 48-hour cultures, followed by 100 μL isopropanol containing 0.04 N HCl. Absorbance was measured at 570/630 nm using a spectrophotometer (Molecular Devices, Sunnyvale, CA). |
| Concentrations | 0~100 μM |
| Incubation time | 24 or 48 h |
| Animal Experiment | |
|---|---|
| Animal models | MM.1S cells xenograft model in Immunodeficient BNX mice |
| Formulation | 0.9% sodium chloride |
| Dosages | daily (36 mg/kg) or weekly (250 mg/kg) |
| Administration | oral |
| Molecular Weight | 461.66 |
| Formula | C25H52NO4P |
| CAS Number | 157716-52-4 |
| Solubility (25°C) | Water 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Akt Products |
|---|
| AT7867
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase with an IC50 of 17 nM. |
| GSK690693
GSK690693 is a potent Akt inhibitor (Akt1 IC50 = 2 nM, Akt2 IC50 = 13 nM, Akt3 IC50 = 9 nM) which also inhibited the phosphorylation of the downstream target GSK3b in cells. |
| MK-2206 2HCl
MK-2206 is a novel allosteric inhibitor of Akt with IC50 values of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. |
| Ipatasertib
Ipatasertib (GDC-0068, RG7440) is a potent and selective, ATP-competitive Akt inhibitor with IC50 values of 5 to 18 nM. |
| Triciribine
Triciribine (API-2, NSC 154020) is a selective inhibitor of Akt (protein kinase B) signaling with IC50 of 130 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
